Details on patient clinical information
| No | Gender (M/F) | Age, years | Disease duration, years | Rheumatoid factor | Anti-CCP antibody | DAS28 (ESR) | Current disease-modifying antirheumatic drug/ glucocorticoid therapy |
|---|---|---|---|---|---|---|---|
| 1 | M | 79 | 1 | Positive | Positive | 8.4 | Nil |
| 2 | F | 66 | 6 | Negative | Negative | 4.3 | Hydroxychloroquine |
| 3 | M | 79 | 1 | Positive | Positive | 4.4 | Methotrexate, prednisolone |
| 4 | F | 67 | 30 | Positive | Positive | 7.1 | Hydroxychloroquine, sulphasalazine |
| 5 | F | 59 | 1 | Positive | Positive | 5.0 | Prednisolone |
| 6 | F | 73 | 18 | Positive | Unknown | 4.5 | Methotrexate |
| 7 | F | 58 | 6 | Positive | Positive | 5.6 | Prednisolone |
| 8 | F | 75 | 40 | Positive | Positive | 4.9 | Methotrexate, sulphasalazine |
| 9 | M | 41 | 6 | Positive | Positive | 5.2 | Methotrexate, adalimumab, prednisolone |
| 10 | F | 55 | 5 | Positive | Positive | 7.5 | Methotrexate |
| 11 | M | 52 | 2 | Positive | Negative | 3.1 | Nil |
| 12 | M | 81 | 0.5 | Positive | Positive | 6.2 | Nil |
Anti-CCP, anti-cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate.